Henry Schein, Inc. (NASDAQ:HSIC) Forecasted to Earn Q4 2017 Earnings of $1.00 Per Share

Henry Schein, Inc. (NASDAQ:HSIC) – Barrington Research upped their Q4 2017 earnings per share (EPS) estimates for shares of Henry Schein in a research report issued to clients and investors on Tuesday, Zacks Investment Research reports. Barrington Research analyst M. Petusky now anticipates that the company will post earnings of $1.00 per share for the quarter, up from their previous forecast of $1.00. Barrington Research also issued estimates for Henry Schein’s Q1 2018 earnings at $0.94 EPS.

A number of other equities research analysts have also recently weighed in on the company. Credit Suisse Group reaffirmed a “hold” rating and set a $87.50 price target on shares of Henry Schein in a report on Tuesday, August 29th. Piper Jaffray Companies upgraded Henry Schein from a “neutral” rating to an “overweight” rating in a research report on Friday, September 15th. Morgan Stanley assumed coverage on Henry Schein in a research report on Thursday, September 21st. They issued an “equal weight” rating and a $88.00 price objective on the stock. UBS AG reiterated a “buy” rating on shares of Henry Schein in a research report on Friday, September 15th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $89.00 price objective on shares of Henry Schein in a research report on Thursday, October 19th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $89.88.

WARNING: “Henry Schein, Inc. (NASDAQ:HSIC) Forecasted to Earn Q4 2017 Earnings of $1.00 Per Share” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://ledgergazette.com/2017/11/13/q4-2017-eps-estimates-for-henry-schein-inc-increased-by-barrington-research-hsic.html.

Henry Schein (NASDAQ HSIC) traded down $2.61 during mid-day trading on Thursday, reaching $67.05. The company had a trading volume of 5,071,400 shares, compared to its average volume of 2,296,728. Henry Schein has a 12-month low of $67.02 and a 12-month high of $93.50. The firm has a market cap of $10,523.77, a PE ratio of 18.81, a price-to-earnings-growth ratio of 1.89 and a beta of 1.03. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.55 and a quick ratio of 0.85.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Monday, November 6th. The company reported $0.87 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.90 by ($0.03). Henry Schein had a net margin of 4.52% and a return on equity of 19.71%. The business had revenue of $3.16 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same period in the prior year, the business earned $0.84 earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis.

Henry Schein announced that its board has initiated a stock buyback plan on Monday, September 18th that permits the company to repurchase $400.00 million in outstanding shares. This repurchase authorization permits the company to reacquire up to 6.3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

In other news, SVP Paul Rose sold 2,126 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $172.51, for a total value of $366,756.26. Following the transaction, the senior vice president now directly owns 17,841 shares in the company, valued at approximately $3,077,750.91. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.19% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of the business. Alecta Pensionsforsakring Omsesidigt raised its stake in shares of Henry Schein by 112.0% in the 3rd quarter. Alecta Pensionsforsakring Omsesidigt now owns 5,313,980 shares of the company’s stock valued at $435,693,000 after purchasing an additional 2,806,990 shares during the period. Janus Henderson Group PLC raised its stake in shares of Henry Schein by 394.1% in the 2nd quarter. Janus Henderson Group PLC now owns 1,465,303 shares of the company’s stock valued at $268,173,000 after purchasing an additional 1,168,763 shares during the period. Swedbank raised its stake in shares of Henry Schein by 84.9% in the 3rd quarter. Swedbank now owns 2,358,594 shares of the company’s stock valued at $193,381,000 after purchasing an additional 1,083,115 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Henry Schein by 102.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,529,279 shares of the company’s stock valued at $125,387,000 after purchasing an additional 775,483 shares during the period. Finally, TimesSquare Capital Management LLC raised its stake in shares of Henry Schein by 131.7% in the 3rd quarter. TimesSquare Capital Management LLC now owns 1,082,600 shares of the company’s stock valued at $88,762,000 after purchasing an additional 615,300 shares during the period. Hedge funds and other institutional investors own 48.16% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Get a free copy of the Zacks research report on Henry Schein (HSIC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply